ReproCell Aktsia

ReproCell EBITDA

EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) ettevõttest ReproCell (4978.T) seisuga 30. juuli 2026 on −111,96 M JPY. Eelmisel aastal oli EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) −393,04 M JPY — muutus −71,52% (kõrgem).

EBITDA

−111,96 MJPY

YoY

−71,52%

Viimati uuendatud:

EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) ettevõttest ReproCell on 2026 −111,96 M JPY. EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) ettevõttest ReproCell oli 2025 −393,04 M JPY. See väheneb −71,52% kõrgem võrreldes eelmise aastaga.
Access this data via the Eulerpool API

ReproCell Aktsiate analüüs

Mida ReproCell teeb? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell on üks populaarsemaid ettevõtteid Eulpoolist.

Sageli esitatud küsimused ReproCell aktsia kohta

ReproCell EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) on 2026. aastal −111,96 M JPY.

Access this data via the Eulerpool API

Kasumi- ja kahjumiaruanne — ReproCell

Kõik finantsnäitajad — ReproCell